

Why we liked Bill Gates' annual letter

Published 25 January 2024

Christopher Gannatti, CFA

Global Head of Research

We have been writing a lot about Artificial Intelligence (AI) and the ways that we believe the topic will continue to evolve as we move into 2024. In 2023, ChatGPT opened the world's eyes to the topic of AI and the concept of 'generative AI'. We saw NVIDIA's incredible business results, as well as some of the world's largest companies making huge investments in AI and showcasing impressive generative AI models.

It's easy to recount history, but much harder to accurately predict future trends. Bill Gates has had a very long career, beginning with founding Microsoft and progressing into primarily philanthropic activities today. Even though we recognise that he cannot accurately predict the future, when people with this much perspective speak — we want to listen.

As CEO of Microsoft in the 1990s, Gates had to steer the company through the world's mass adoption of the internet. He had to make a lot of predictions to position the firm for success amidst an uncertain backdrop. Therefore, if he is choosing to write about AI, and what he sees as important in the megatrend's upcoming evolution, it's notable both that he made the choice to cover this topic at all, and that what he chooses to focus on could be an interesting signal, given his insight into different technologies.

In his letter Gates posed five questions to discuss the future of AI1:

- Can AI combat antibiotic resistance?
- Can AI bring personalised tutors to every student?
- Can AI help treat high-risk pregnancies?
- Can AI help people assess their risk of human immunodeficiency virus (HIV)?
- Can AI make medical information easier to access for every health worker?

Each of these questions is extremely important, and when Gates is focusing on them he is working toward using any benefits to help the massive numbers – the billions – in the world's poorest economic situations. We investigated each of the five areas to identify any advances being publicised and whether those advances focused on the poorest, most at-risk, groups.

Antibiotic Resistance2

On 20 December 2023 researchers at MIT reported that they had used AI to discover a class of compounds that can kill a drug-resistant strain of staphylococcus aureus. They also noted that the compounds showed a very low toxicity against human cells, which is important when considering it as a drug candidate.

A common critique of deep-learning-based AI models, like those used in the study, is that they can be black boxes. Maybe you get an interesting answer, maybe not, and good luck understanding the 'why' in terms of what was or wasn't suggested. However, these researchers have not only made advancements on identifying possible compounds, but also in designing a model that's outputs are more explainable. An effective model, at least in theory, should also be able to adapt current therapies or identify new options to keep pace against future resistance.

Personalised Tutors³

It is interesting to consider how our trust for different types of digital information evolves. I graduated from college in 2006, and in that period the idea of using Wikipedia as a source in a paper would have been unheard of. Now, at the start of 2024, Wikipedia might be one of the most trusted sources on the internet.

The concept of using generative AI as a tutor, or as a foundation from which tutoring applications can be built, is in its early stages. There are articles that discuss possible best practices, in terms of prompting the student, but it's clear that the technology itself should be able to perform this function. I remember having to call classmates or wait for individual time with the teacher to discuss my queries, whereas students today can be stuck on a question and ask for suggested approaches, or ways of thinking, in almost real time.

High risk pregnancies⁴

We can agree that there are many sources of risk in pregnancies, so it is unrealistic to assume we can design a system to help with all of them. We did, however, find a system that mitigated the risk of high stress in pregnancy. It used a combination of heart rate monitoring and a smartphone application to predict if the next day would be particularly stressful for the pregnant person and if it was the system would offer suggestions and support to mitigate this.

While not a guaranteed solution, at least attempting to lower stress levels in pregnant people could be somewhat valuable. We'd imagine that, in the future, more distinct systems created to manage specific risks could evolve.

Assessment of HIV Risk⁵

Of the five areas identified by these questions, this was the question most directly focused on the world's more vulnerable populations, and one that the Bill & Melinda Gates Foundation identifies as its core focus.

On the Bill & Melinda Gates Foundation website, we found a note titled, "Your Choice: Using AI to Reduce Stigma and Improve Precision in HIV Risk Assessments." 'Your Choice' is an acronym for Your Own Unique Risk Calculation for HIV-related Outcomes and Infections using a Chat Engine.

It is designed to help with the epidemic in South Africa. Gathering accurate sexual history is essential in assessing HIV risk, so using an LLM to ensure privacy and confidentiality – as well as improving the accuracy of risk assessments and suggesting treatment options – could be beneficial. A system like this would also be available 24/7.

Medical information management⁶

Have you ever looked at your own medical chart in a doctor's office?

In the US, there is a sense that if you work with different doctors that any information that needs to be shared between medical professionals is shared. However, despite giving written consent, it may not always be clear how this information is being shared. And in developing countries, it may be impossible for that information to be shared at all.

When sharing information privacy is the primary concern, therefore any developments in this area need to be pragmatic. If we can assume that there is a stepwise progression that can account for privacy in an appropriate way, consider this scenario. We know that systems like YouTube, TikTok and Netflix successfully record what you engage with and feed you more of what people like you have found interesting to keep you engaged on the platform. In medicine, each individual person is different, but many groups of people can exhibit similarities. Without needing to know individual names, it could be possible to see broad-based population statistics on people who have similar data. This information could help to define key risks, treatment options, and other important information. The concept could empower people, allowing them to better understand and discuss possible treatment options with their doctors.

So far, at least from what we can see, this area is more theory than practice, but there is no reason in the technology itself why it couldn't be possible.

Conclusion: Alignment with our previously mentioned biotechnology turnaround thesis

We have written numerous times recently about how we believe that, after a very difficult couple of years, biotechnology companies may see a rebound in returns during 2024. Bill Gates can write about the intersection of AI with many different avenues of technology, but he chose to focus on medicine and health care.

For those looking for specific companies that reflect notable activities in the biotechnology sphere, check out the [WisdomTree Biorevolution UCITS ETF \(Ticker: WDNA\)](#).

1 Source: <https://www.gatesnotes.com/The-Year-Ahead-2024>

2 Source: Trafton, Anne. "Using AI, MIT researchers identify a new class of antibiotic candidates." MIT News. December 20, 2023.

3 Source: Mollick, Ethan & Lilach. "Customizing the Student Learning Experience." HBR. September 25, 2023.

4 Source: Azzo, Andrea. "Patient-Focused AI System Seeks to Reduce Stress during Pregnancy." Center for Advancing Safety of Machine Intelligence. September 22, 2023.

5 Source: Pascoe, Sophie. "'Your Choice': Using AI to Reduce Stigma and Improve Precision in HIV Risk Assessments." Bill & Melinda Gates Foundation. June 18, 2023.

6 Bhasker et al. "Tackling healthcare's biggest burdens with generative AI." McKinsey & Company. July 2023.

Related blogs

+ [Is it Time for Biotech?](#)

+ [When megatrends collide, lives could be saved](#)

Important Risks Related to this Article

IMPORTANT INFORMATION

Marketing communications issued in the European Economic Area (“EEA”): This document has been issued and approved by WisdomTree Ireland Limited, which is authorised and regulated by the Central Bank of Ireland.

Marketing communications issued in jurisdictions outside of the EEA: This document has been issued and approved by WisdomTree UK Limited, which is authorised and regulated by the United Kingdom Financial Conduct Authority.

WisdomTree Ireland Limited and WisdomTree UK Limited are each referred to as “WisdomTree” (as applicable). Our Conflicts of Interest Policy and Inventory are available on request.

For professional clients only. Past performance is not a reliable indicator of future performance. Any historical performance included in this document may be based on back testing. Back testing is the process of evaluating an investment strategy by applying it to historical data to simulate what the performance of such strategy would have been. Back tested performance is purely hypothetical and is provided in this document solely for informational purposes. Back tested data does not represent actual performance and should not be interpreted as an indication of actual or future performance. The value of any investment may be affected by exchange rate movements. Any decision to invest should be based on the information contained in the appropriate prospectus and after seeking independent investment, tax and legal advice. These products may not be available in your market or suitable for you. The content of this document does not constitute investment advice nor an offer for sale nor a solicitation of an offer to buy any product or make any investment.

An investment in exchange-traded products (“ETPs”) is dependent on the performance of the underlying index, less costs, but it is not expected to match that performance precisely. ETPs involve numerous risks including among others, general market risks relating to the relevant underlying index, credit risks on the provider of index swaps utilised in the ETP, exchange rate risks, interest rate risks, inflationary risks, liquidity risks and legal and regulatory risks.

The information contained in this document is not, and under no circumstances is to be construed as, an advertisement or any other step in furtherance of a public offering of shares in the United States or any province or territory thereof, where none of the issuers or their products are authorised or registered for distribution and where no prospectus of any of the issuers has been filed with any securities commission or regulatory authority. No document or information in this document should be taken, transmitted or distributed (directly or indirectly) into the United States. None of the issuers, nor any securities issued by them, have been or will be registered under the United States Securities Act of 1933 or the Investment Company Act of 1940 or qualified under any applicable state securities statutes.

This document may contain independent market commentary prepared by WisdomTree based on publicly available information. Although WisdomTree endeavours to ensure the accuracy of the content in this

document, WisdomTree does not warrant or guarantee its accuracy or correctness. Any third party data providers used to source the information in this document make no warranties or representation of any kind relating to such data. Where WisdomTree has expressed its own opinions related to product or market activity, these views may change. Neither WisdomTree, nor any affiliate, nor any of their respective officers, directors, partners, or employees accepts any liability whatsoever for any direct or consequential loss arising from any use of this document or its contents.

This document may contain forward looking statements including statements regarding our belief or current expectations with regards to the performance of certain assets classes and/or sectors. Forward looking statements are subject to certain risks, uncertainties and assumptions. There can be no assurance that such statements will be accurate and actual results could differ materially from those anticipated in such statements. WisdomTree strongly recommends that you do not place undue reliance on these forward-looking statements.

The products discussed in this document are issued by WisdomTree Issuer ICAV ("WT Issuer"). WT Issuer is an umbrella investment company with variable capital having segregated liability between its funds organised under the laws of Ireland as an Irish Collective Asset-management Vehicle and authorised by the Central Bank of Ireland ("CBI"). WT Issuer is organised as an Undertaking for Collective Investment in Transferable Securities ("UCITS") under the laws of Ireland and shall issue a separate class of shares ("Shares") representing each fund. Investors should read the prospectus of WT Issuer ("WT

Prospectus") before investing and should refer to the section of the WT Prospectus entitled »Risk Factors^{1/4} for further details of risks associated with an investment in the Shares.

Notice to Investors in Switzerland – Qualified Investors

This document constitutes an advertisement of the financial product(s) mentioned herein. The prospectus and the key **investor information documents (KIID) are available from WisdomTree^{1/4}s web-site**: <https://www.wisdomtree.eu/en-ch/resource-library/prospectus-and-regulatory-reports> Some of the sub-funds referred to in this document may not have not been registered with the Swiss Financial Market Supervisory Authority ("FINMA"). In Switzerland, such sub-funds that have not been registered with FINMA shall be distributed exclusively to qualified investors, as defined in the Swiss Federal Act on Collective Investment Schemes or its implementing ordinance (each, as amended from time to time). The representative and paying agent of the sub-funds in Switzerland is Société Générale Paris, Zurich Branch, Talacker 50, PO Box 5070, 8021 Zurich, Switzerland. The prospectus, the key investor information documents (KIID), the articles of association and the annual and semi-annual reports of the sub-funds are available free of charge from the representative and paying agent. As regards distribution in Switzerland, the place of jurisdiction and performance is at the registered seat of the representative and paying agent.

For Investors in France

The information in this document is intended exclusively for professional investors (as defined under the MiFID) investing for their own account and this material may not in any way be distributed to the public. The distribution of the Prospectus and the offering, sale and delivery of Shares in other jurisdictions may

be restricted by law. WT Issuer is a UCITS governed by Irish legislation, and approved by the Financial Regulatory as UCITS compliant with European regulations although may not have to comply with the same rules as those applicable to a similar product approved in France. The Fund has been registered for marketing in France by the Financial Markets Authority (Autorité des Marchés Financiers) and may be distributed to investors in France. Copies of all documents (i.e. the Prospectus, the Key Investor Information Document, any supplements or addenda thereto, the latest annual reports and the memorandum of incorporation and articles of association) are available in France, free of charge at the French centralizing agent, Societe Generale at 29, Boulevard Haussmann, 75009, Paris, France. Any subscription for Shares of the Fund will be made on the basis of the terms of the prospectus and any supplements or addenda thereto.

For Investors in Malta

This document does not constitute or form part of any offer or invitation to the public to subscribe for or purchase shares in the Fund and shall not be construed as such and no person other than the person to whom this document has been addressed or delivered shall be eligible to subscribe for or purchase shares in the Fund. Shares in the Fund will not in any event be marketed to the public in Malta without the prior authorisation of the Maltese Financial Services Authority.

For Investors in Monaco

This communication is only intended for duly registered banks and/or licensed portfolio management companies in Monaco. This communication must not be sent to the public in Monaco.